A marijuana-derived spray, which contains THC and cannobidiol — a non-psychoactive cannabinoid, has been approved for use by Canadians with advanced cancer.
Canadian health officials have approved the medication to provide cancer patients with another option when it comes to dealing with pain.
"It's the brave new world of pain management," Dr. Allan Gordon, director of the Wassar Pain Management Clinic at Mt. Sinai Hospital in Toronto, told the Edmonton Sun.
The drug, called Sativex, was approved by Health Canada last week with the condition that further testing would be done to confirm the promising nature of the clinical trials that have been conducted.
Gordon said Sativex, which is primarily composed of components from the cannabis plant, hasn't produced any adverse side-effects in patients, something other pain medications, particularly opioids, can't claim.